HBT Labs

Contact Us!

Don Hodgson

President and Co-founder

Don Hodgson is the president of HBT Labs, a role he has held since the company was founded in 2013 to focus on the development of complex injectable pharmaceutical products. Dr. Hodgson received a B.A. in chemistry from the University of California, Berkeley and a Ph.D. in physical chemistry from the University of Southern California.

Dr. Hodgson has been involved in the pharmaceutical industry for over 25 years. Prior to taking on his role at HBT Labs, Dr. Hodgson served as the director of manufacturing and technical operations for Eyetech Pharmaceuticals and as the senior director of pharmaceutical development for NeXstar Pharmaceuticals. He has consulted for several biotechnology and pharmaceutical companies with particular focus on developing complex drug products and aseptic manufacturing systems. Dr. Hodgson has vast knowledge and experience in the formulation and process development of long-acting injectable products, nanoparticles, liposomes, and emulsions.

JANET BRAUN

Chief Operating Officer and General Counsel

Janet Braun has served as the chief operating officer and general counsel of HBT Labs since 2017. Prior to that, she served as a consultant to the company. Ms. Braun earned both a B.S. in industrial and systems engineering and her J.D. with honors from Ohio State University.

Ms. Braun began her legal career as a corporate lawyer at O’Melveny & Myers in Los Angeles. She also served as associate general counsel at Santa Fe International Corporation, an international oil drilling services company, and as associate general counsel and corporate secretary at NeXstar Pharmaceuticals, Inc. She has served on the boards of several nonprofit organizations including the Greater Los Angeles Area Council of the Boy Scouts of America, Pasadena Ronald McDonald House, American Youth Soccer Association, and Flintridge Preparatory School.

YAN CHANG

Director, Pharmaceutical Research and Development

Yan Chang joined HBT Labs in 2014 as the director of pharmaceutical research and development. She earned both her bachelor’s degree in chemistry and a master’s degree in analytical chemistry from Shaxni University in China. She earned her Ph.D. in pharmaceutical analytical chemistry at the Institute of Materia Medica, Chinese Academy of Sciences, and Peking Union Medical College. Dr. Chang also earned a Ph.D. from the University of Southern California.

Dr. Chang has published research articles in more than 20 publications. Before joining HBT Labs, she worked at the University of Southern California as a senior research/associate manager of USC’s Department of Preventive Medicine, Environmental Health, and Biomarkers Analysis Laboratory.

Jack Liu

Controller

Prior to joining HBT Labs as controller in 2020, Jack Liu was controller for Dendron Pharmaceuticals. His extensive finance experience includes roles as an audit supervisor in PricewaterhouseCoopers’ Department of Assurance/Business Advisory Service and as an audit senior associate at KPMG. Mr. Liu received his B.S. in Accounting from Chinese Culture University’s School of Business in Taiwan and did graduate study in Administrative Studies at University of South Dakota.

Maribelle Guloy

Director, Clinical Development

Maribelle Guloy is the director of clinical development at HBT Labs. She holds a Doctor of Health Science (DHS) degree in global health and has over 20 years of clinical experience. Prior to joining HBT Labs, Ms. Guloy was the director of clinical research at Clinical Trials and Research Associates, Inc., and later served as director of clinical operations for WCCT Global/Medelis.

ALBERT CHOU

Director, Quality Control

Albert Chou has been the director of quality control for HBT Labs since January 2014, overseeing QC and Microbiology. He earned a bachelor’s degree in bioengineering from University of California San Diego and received his master’s degree in biotechnology from Cal Poly Pomona in 2012. Mr. Chou has held positions as a research assistant at AVIVA Biosciences and the Rebecca and John Moores Cancer Center, and worked as a senior chemist at Watson Pharmaceuticals in Corona, CA.

JOELLE YANG

Manager, Quality Assurance

Joelle Yang joined HBT Labs as the manager of quality assurance in 2018, bringing more than 20 years of experience in the pharmaceutical industry. She holds a B.S. in chemistry from University of California Irvine. Prior to joining HBT Labs, Ms. Yang was a quality investigator at Teva Pharmaceuticals, a senior quality engineer at Actavis Generics, and a research scientist Watson Pharmaceuticals.

Maria Park

Validation, Maintenance and Metrology Manager

Maria Park was HBT Lab’s validation lead for two years before assuming her current role. Her experience in manufacturing protocols includes roles as a quality assurance lab technician at Popchips and a validation engineer at Amphastar Pharmaceuticals, Inc. She holds a B.S. in Biology and a minor in Neuroscience from University of California Riverside.

Content title

Content tagline Here

"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum."

Content title

Content tagline Here

Content title

Content tagline Here

Content title

Content tagline Here

AN EXTENSIVE PRODUCT PIPELINE

Applications Filed and Approved by the USDA

In 2019, the FDA approved HBT’s Abbreviated New Drug Application to market and sell its Fulvestrant product, a generic equivalent to Faslodex®, for the treatment of certain types of breast cancer. In early 2020, through its marketing partner, HBT Labs launched commercial sales of Fulvestrant in the US.

In 2018, HBT Labs filed a New Drug Application with the FDA under Section 505(b)(2) for approval to market and sell HBT’s Paclitaxel product for the treatment of certain types of breast cancer.

FULVESTRANT INJECTION

HBT’s Fulvestrant

Container Type	Prefilled Syringe
Strength	250 mg per 5 mL
Concentration	50 mg per mL
Fill Volume	5 mL
Syringe Size	5 mL

Our mission is to develop and deliver cost-effective, high-quality therapeutics for patients in critical need.